Find in Library

Background:       Carcinoma  breast  is  most  commonly  diagnosed  cancer  at  present. Due  to  systemic  nature  of  disease,  chemotherapy  plays  an  important  role  in  treatment  of  carcinoma breast.  Relapse (loco-regional or metastatic)  is  not  uncommon  in  this  disease.  Both  eribulin  and  capecitabine  are  effective  as  single  agent  in  relapsed  disease.  In  this  single-institutional  retrospective  study,  eribulin  and  capecitabine  have  been used  as  combination  chemotherapy regimen in patients  with  relapsed  carcinoma  breast.   Marerials and methods:       Patients  diagnosed  to  have  relapsed  carcinoma  of  breast,   who  were  ER and/or  PR positive,  Her-2/neu negative  or  triple negative  and  received  eribulin  alongwith capecitabine,  were  included  in  our  study.  Primary  objective  of  this  study  was  to  assess  response,  progression-free  survival (PFS)  and  overall  survival (OS).  Secondary objective  was  toxicity  assessment. Results:      48  patients  were  included  in  our  study.  Median  age  of  patients  was  56 years.  Thirty six (75%)  patients  had  ER and/or PR positive status  and  twelve (25%)  patients  had  ER/PR negative  status. Five (10.4%)  patients  achieved  complete  response (CR).  Thirty two (66.7%)  patients  achieved  partial  response (PR).  Disease  was  stable (SD)  in  nine (18.8%) patients.  Two (4.2%) patients  suffered  from  progressive  disease (PD).  Median   Progression-free survival (PFS)  was  10.15 months.  Mean  of  PFS  of  patients  was  10.72 (95% CI- 9.72-11.72)  months.  Median  overall survival (OS)  was  18.15 months.  Mean  of  overall  survival of  patients  was  19.56 (95% CI- 17.9-21.22) months.      Nineteen (39.6%)  and  three (6.2%)  patients  experienced  grade 2  and  grade 3  anemia  respectively.  Eighteen (37.5%)  and  two (4.2%)  patients  suffered  from  grade 2  and  grade 3 neutropenia  respectively.  One  patients  experienced  grade 2  thrombocytopenia.  Nineteen (39.6%)  patients  experienced  grade 2  diarrhoea.  One  patients  suffered  from  grade 3 diarrhoea.  Palmo-plantor  erythrodysesthesia  was  seen  in  eight (16.7%)  patients. Six (12.5%) patients  suffered  from  grade 2  neuropathy. Two (4.2%)  patients  experienced  grade 3 neuropathy.  Fatigue  was  seen  in  19 (39.6%)  patients. Conclusion:     Eribulin  alongwith  capectabine  can  be  used  in  patients  with  relapsed  carcinoma  breast,  in  whom  anthracycline  and  taxane  have  previously  been  used;  with response  rate  and  survival  better  than  either  single  agent  chemotherapy.  This  regimen  is  important  particularly  for  TNBC,  where  option  for  chemotherapy  is  limited.